Skip to main content

Table 1 Main SS-related features of patients according to the presence or absence of serum HCV-IgG antibodies

From: How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients

 

Negative HCV-IgG

Positive HCV-IgG

Bilateral P value

N = 678

N = 105

Mean age, years

56.36 ± 14.83

62.93 ± 11.86

<0.001*

Sex, male

45 (7 %)

17 (16 %)

0.003

Dry mouth

661 (98 %)

103 (98 %)

1

Dry eye

661 (98 %)

104 (99 %)

0.493

Altered ocular tests

559/609 (92 %)

82/88 (93 %)

0.834

Altered parotid scintigraphy

486/554 (88 %)

45/54 (83 %)

0.389

Positive salivary gland biopsy

198/309 (64 %)

21/30 (70 %)

0.556

Criteria SS

 - 1993 only

230 (34 %)

54 (51 %)

<0.001

 - 2002

432 (64 %)

38 (26 %)

 - ACR only

16 (2 %)

13 (12 %)

Antinuclear antibody+

568/676 (84 %)

79/104 (76 %)

0.05

Rheumatoid factor+

267/663 (40 %)

57/102 (56 %)

0.004

Anti-Ro/SS-A+

292/676 (43 %)

16/103 (15 %)

<0.001*

Anti-La/SS-B+

200/676 (30 %)

17/103 (17 %)

0.006

Monoclonal gammopathy

85/492 (17 %)

35/75 (47 %)

<0.001

Type of monoclonal band

 - mIgA

9 (11 %)

1 (3 %)

0.047

 - mIgG

47 (55 %)

13 (37 %)

 - mIgM

18 (21 %)

15 (43 %)

 - Free chains

11 (13 %)

6 (17 %)

Type of monoclonal light chain

 - Kappa:lambda

50:35

19:16

0.65

Cryoglobulin+

41/626 (7 %)

63/104 (61 %)

<0.001*

Low C3 levels, <0.82 g/l

70/660 (11 %)

37/103 (36 %)

<0.001*

Low C4 levels, <0.11 g/l

45/660 (7 %)

49/103 (48 %)

<0.001*

Hematological neoplasia

26 (4 %)

9 (9 %)

0.04*

Neoplasia

54 (8 %)

21 (20 %)

<0.001*

Death

52 (8 %)

35 (33 %)

<0.001

  1. *Statistically significant in the multivariate model.
  2. SS Sjögren syndrome, HCV hepatitis C virus, IgG immunoglobulin G, ACR American College of Rheumatology, SS-A Sjögren syndrome A antigen, SS-B Sjögren syndrome B antigen, mIg circulating monoclonal immunoglobulin, C3 complement component 3, C4 complement component 4Bold numbers: statistically-significant differences in the univariate analysis (p<0.05)